The Trump administration has begun negotiating drug-pricing agreements directly with smaller biotechnology companies, STAT reported, citing three people with knowledge of the meetings. The talks mark an expansion of White House pricing pressure beyond large pharmaceutical companies.
The negotiations appear driven in part by tariff threats. Smaller biotechs are moving to the table as they face potential tariffs on imported active pharmaceutical ingredients, finished drug products, and manufacturing inputs. Bitget noted the sector faces regulatory uncertainty, caught between pricing concessions and tariffs potentially as high as 200%.
For genomics and molecular diagnostics, the implications center on companion diagnostic economics. Biotech companies developing targeted therapies paired with companion diagnostics—the model underpinning much precision medicine commercialization—face direct pressure on therapeutic margins. If pricing concessions compress drug-side revenues, investment in co-developed diagnostic programs could decline, reducing pipeline opportunities for diagnostics suppliers.
Smaller biotechs that depend on premium pricing to recoup development costs for orphan drugs and genetically targeted therapies may slow or restructure clinical programs, rippling through contract research and sequencing services markets.
The administration's bilateral negotiation approach—rather than industry-wide rulemaking—creates uncertainty. Companies reaching early agreements may secure more favorable terms, while holdouts risk tariff exposure. STAT reported some smaller firms are proactively seeking meetings. The identities of companies in active negotiations have not been disclosed.
The pricing pressure arrives alongside federal budget constraints. As BaseCall reported this week, the Trump administration reversed a proposed NIH indirect-cost cap but still faces a proposed $5 billion fiscal 2027 budget cut that has disrupted 25% of NIH-funded researchers.